| Nov 19 |
Incyte Is the S&P 500’s Worst Performer Today. What’s Hitting the Stock.
|
| Nov 19 |
Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges
|
| Nov 19 |
Incyte Faces Challenges but Remains Focused on Strategic Growth
|
| Nov 19 |
Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.
|
| Nov 19 |
Incyte sinks on setback for drugs acquired in $750M buyout
|
| Nov 18 |
Incyte drops 9% after pausing enrollment in study for urticaria asset
|
| Nov 18 |
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs
|
| Nov 18 |
Is Incyt Corporation (INCY) the Best Immunotherapy Stock to Buy Now?
|
| Nov 16 |
Here’s How Jakafi’s Patent Expiry Impacts Incyte Corporation’s (INCY) Growth Prospects
|
| Nov 14 |
Incyte to Present at Upcoming Investor Conference
|
